收费全文 | 2356193篇 |
免费 | 195703篇 |
国内免费 | 4094篇 |
耳鼻咽喉 | 34202篇 |
儿科学 | 72466篇 |
妇产科学 | 62897篇 |
基础医学 | 331849篇 |
口腔科学 | 67433篇 |
临床医学 | 213565篇 |
内科学 | 462638篇 |
皮肤病学 | 47886篇 |
神经病学 | 199220篇 |
特种医学 | 95818篇 |
外国民族医学 | 886篇 |
外科学 | 359336篇 |
综合类 | 56160篇 |
一般理论 | 980篇 |
预防医学 | 188860篇 |
眼科学 | 55282篇 |
药学 | 176975篇 |
4篇 | |
中国医学 | 4257篇 |
肿瘤学 | 125276篇 |
2018年 | 23909篇 |
2016年 | 20335篇 |
2015年 | 23042篇 |
2014年 | 33430篇 |
2013年 | 50737篇 |
2012年 | 68758篇 |
2011年 | 72282篇 |
2010年 | 42391篇 |
2009年 | 40783篇 |
2008年 | 68765篇 |
2007年 | 73092篇 |
2006年 | 73983篇 |
2005年 | 71984篇 |
2004年 | 69296篇 |
2003年 | 66944篇 |
2002年 | 66150篇 |
2001年 | 112319篇 |
2000年 | 116273篇 |
1999年 | 97739篇 |
1998年 | 26171篇 |
1997年 | 23804篇 |
1996年 | 23754篇 |
1995年 | 24475篇 |
1994年 | 23051篇 |
1993年 | 21450篇 |
1992年 | 79295篇 |
1991年 | 76404篇 |
1990年 | 73552篇 |
1989年 | 70808篇 |
1988年 | 65806篇 |
1987年 | 64784篇 |
1986年 | 61311篇 |
1985年 | 58378篇 |
1984年 | 44164篇 |
1983年 | 37565篇 |
1982年 | 22811篇 |
1981年 | 20241篇 |
1980年 | 18947篇 |
1979年 | 41231篇 |
1978年 | 28918篇 |
1977年 | 24241篇 |
1976年 | 22694篇 |
1975年 | 23866篇 |
1974年 | 29550篇 |
1973年 | 27977篇 |
1972年 | 26185篇 |
1971年 | 24127篇 |
1970年 | 22720篇 |
1969年 | 21052篇 |
1968年 | 19110篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献